JP2025508004A5 - - Google Patents
Info
- Publication number
- JP2025508004A5 JP2025508004A5 JP2024552730A JP2024552730A JP2025508004A5 JP 2025508004 A5 JP2025508004 A5 JP 2025508004A5 JP 2024552730 A JP2024552730 A JP 2024552730A JP 2024552730 A JP2024552730 A JP 2024552730A JP 2025508004 A5 JP2025508004 A5 JP 2025508004A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- migraine
- atgepant
- baseline
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269105P | 2022-03-09 | 2022-03-09 | |
| US63/269,105 | 2022-03-09 | ||
| US202263347265P | 2022-05-31 | 2022-05-31 | |
| US63/347,265 | 2022-05-31 | ||
| US202263404352P | 2022-09-07 | 2022-09-07 | |
| US63/404,352 | 2022-09-07 | ||
| US202363480365P | 2023-01-18 | 2023-01-18 | |
| US63/480,365 | 2023-01-18 | ||
| PCT/US2023/064027 WO2023173005A2 (en) | 2022-03-09 | 2023-03-09 | Preventive treatment of migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508004A JP2025508004A (ja) | 2025-03-21 |
| JP2025508004A5 true JP2025508004A5 (https=) | 2026-03-09 |
Family
ID=87936018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552730A Pending JP2025508004A (ja) | 2022-03-09 | 2023-03-09 | 片頭痛の予防的治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230321055A1 (https=) |
| EP (1) | EP4489856A4 (https=) |
| JP (1) | JP2025508004A (https=) |
| CN (1) | CN119421710A (https=) |
| AU (1) | AU2023231645A1 (https=) |
| CA (1) | CA3244873A1 (https=) |
| MX (1) | MX2024010878A (https=) |
| WO (1) | WO2023173005A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190374520A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20210121541A1 (en) * | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
| CN116390712A (zh) * | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
-
2023
- 2023-03-09 MX MX2024010878A patent/MX2024010878A/es unknown
- 2023-03-09 CA CA3244873A patent/CA3244873A1/en active Pending
- 2023-03-09 AU AU2023231645A patent/AU2023231645A1/en active Pending
- 2023-03-09 EP EP23767687.9A patent/EP4489856A4/en active Pending
- 2023-03-09 WO PCT/US2023/064027 patent/WO2023173005A2/en not_active Ceased
- 2023-03-09 CN CN202380026078.8A patent/CN119421710A/zh active Pending
- 2023-03-09 US US18/181,228 patent/US20230321055A1/en active Pending
- 2023-03-09 JP JP2024552730A patent/JP2025508004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508004A5 (https=) | ||
| JP2023535744A5 (https=) | ||
| JP2020510016A5 (https=) | ||
| JP2024533756A5 (https=) | ||
| JP2023500032A5 (https=) | ||
| JP2021529829A5 (https=) | ||
| JP2023545372A5 (https=) | ||
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2020522560A5 (https=) | ||
| JP2005508896A5 (https=) | ||
| JP4290764B2 (ja) | ヒトおよび動物のボルナ病ウイルスへの感染防止、ならびに情動障害およびｂｄｖ感染に関連するその他の障害の予防および治療に対するアダマンタンアミンまたはその構造的類縁化合物の使用 | |
| JP2023523706A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2023549849A5 (https=) | ||
| JP2025517509A5 (https=) | ||
| JPWO2020022507A5 (https=) | ||
| JP2024540439A5 (https=) | ||
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| CN115279344A (zh) | 盐酸米托蒽醌脂质体的用途 | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| JP2023537369A5 (https=) | ||
| JP2023520929A5 (https=) | ||
| JP2022543598A5 (https=) | ||
| JP2024522163A5 (https=) |